- On November 19, the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
- On March 31, 2020, the Company entered into an agreement with Tecnologico de Monterrey, the leading university in Mexico, to educate physicians across Latin America, in advance of the impending regulations in Mexico
- To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
- The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico, building on the success of its vertical integration strategy in Colombia
- Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
- Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
- Company to release Q3 2020 financials and host webcast on Tuesday, December 1st
TORONTO, Nov. 27, 2020 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe,…
Original Author Link click here to read complete story..